A busy clinical team at Regeneron $REGN and Sanofi $SNY has outlined another segment on the allergic inflammatory map that they plan to build their Dupixent kingdom upon.
In two Phase III trials, investigators say, the mega-blockbuster hopeful delivered a clean sweep over chronic rhinosinusitis with nasal polyps, clearing obstruction and shrinking abnormal tissue growth at a much higher rate than placebo.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,